[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatitis Treatment Market, 2012 to 2023

January 2018 | 202 pages | ID: HEDBE2E0CFCEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Hepatitis Treatment Market: By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Others), By Drug Type (Vaccines, Anti-Viral Drugs, Interferons, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Market Outline: Hepatitis Treatment Market

Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies.

Market Dynamics: Hepatitis Treatment Market

Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast timeframe.

Market Scope: Hepatitis Treatment Market

Hepatitis treatment market is segmented on the basis of disease type, drug type, route of administration, distribution channel, and region

Based on disease type, the market is segmented into the following:

Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Others

Based on the drug type, the market is segmented into the following:

Vaccines
Anti-Viral Drugs
Interferons
Others

Based on the route of administration, the market is segmented into the following:

Oral
Parenteral

Based on the distribution channel, the market is segmented into the following:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Based on the region, the market is segmented into the following:

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Market Summary: Hepatitis Treatment Market

Global hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the hepatitis treatment market. For instance, in June 2016, FDA approved Epclusa manufactured by Gilead Sciences, Inc. used in the treatment of chronic hepatitis C virus infection. Moreover, in May 2017, Eiger Biopharmaceuticals filed investigational new drug application with FDA for Lambda (pegylated interferon lambda 1a) for the treatment of hepatitis D.

Regional Analysis: Hepatitis Treatment Market

Geographically, global hepatitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America hepatitis treatment market is poised to grow due to increase in the prevalence of hepatitis infection, the rise in R&D activities for the innovation of new drugs, an increase in healthcare expenditure in the region. Europe hepatitis treatment market expected to exhibit lucrative growth owing to rise in prevalence of hepatitis due to change in lifestyle, increase in awareness about the hepatitis treatment, and adoption of newer drugs and vaccines are propelling the market. Asia Pacific hepatitis treatment market is growing due to increase in the geriatric population in India, China, and Japan, the rise in healthcare expenditure, and launching of generic drugs into the market. Latin America hepatitis treatment market is driven by an increase in hepatitis C infection, launching of newer products into the market, and increase in the awareness about hepatitis treatment. Middle East and Africa hepatitis treatment market’s growth is attributed to economic growth, increase in the prevalence of hepatitis infection in African countries, and expansion of businesses by market players in the region.

Competition Assessment: Hepatitis Treatment Market

Some of the players in the global hepatitis treatment market include:

Hoffmann- La Roche Ltd. (Switzerland)
Gilead Sciences (U.S.)
Novartis AG (Switzerland)
Bristol-Myers Squibb (U.S)
GlaxoSmithKline, plc.
Merck and Co, Inc. (U.S)
Johnson & Johnson Services, Inc. (U.S.)
AbbVie Inc. (U.S.)
Novira Therapeutics Inc. (U.S.)
Eiger Biopharmaceuticals (U.S.)

Notable Market Developments: Hepatitis Treatment Market

In September 2017, China Food and Drug Administration approved Gilead’s Sovaldi (Sofosbuvir) used in the treatment of chronic HCV infection
1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS TREATMENT MARKET INTRODUCTION

2.1. Global Hepatitis Treatment Market – Taxonomy
2.2. Global Hepatitis Treatment Market –Definitions
  2.2.1. Disease Type
  2.2.2. Drug Type
  2.2.3. Route of Administration
  2.2.4. Distribution Channel

3. GLOBAL HEPATITIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis- Epidemiology
3.6. Global Hepatitis Treatment Market Dynamics – Factors Impact Analysis
3.7. Global Hepatitis Treatment Market – Regulations
  3.7.1. U.S.
  3.7.2. Europe
3.8. Global Hepatitis Treatment Market –Pipeline Analysis

4. GLOBAL HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL HEPATITIS TREATMENT MARKET, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Hepatitis A
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Hepatitis B
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Hepatitis C
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Hepatitis D
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Hepatitis E
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Others
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL HEPATITIS TREATMENT MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Vaccines
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Anti-Viral Drugs
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Interferons
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL HEPATITIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Parenteral
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis

8. GLOBAL HEPATITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Others
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis

9. GLOBAL HEPATITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Hepatitis A
  10.1.2. Hepatitis B
  10.1.3. Hepatitis C
  10.1.4. Hepatitis D
  10.1.5. Hepatitis E
  10.1.6. Others
10.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Vaccines
  10.2.2. Anti-Viral Drugs
  10.2.3. Interferons
  10.2.4. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Oral
  10.3.2. Parenteral
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Hospital Pharmacies
  10.4.2. Retail Pharmacies
  10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.5.1. U.S.
  10.5.2. Canada
10.6. North America Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Hepatitis Treatment Market Dynamics – Trends

11. EUROPE HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Hepatitis A
  11.1.2. Hepatitis B
  11.1.3. Hepatitis C
  11.1.4. Hepatitis D
  11.1.5. Hepatitis E
  11.1.6. Others
11.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Vaccines
  11.2.2. Anti-Viral Drugs
  11.2.3. Interferons
  11.2.4. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Oral
  11.3.2. Parenteral
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Hospital Pharmacies
  11.4.2. Retail Pharmacies
  11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.5.1. Germany
  11.5.2. UK
  11.5.3. France
  11.5.4. Spain
  11.5.5. Italy
  11.5.6. Russia
  11.5.7. Poland
  11.5.8. Rest of Europe
11.6. Europe Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Hepatitis Treatment Market Dynamics – Trends

12. ASIA-PACIFIC HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Hepatitis A
  12.1.2. Hepatitis B
  12.1.3. Hepatitis C
  12.1.4. Hepatitis D
  12.1.5. Hepatitis E
  12.1.6. Others
12.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Vaccines
  12.2.2. Anti-Viral Drugs
  12.2.3. Interferons
  12.2.4. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Oral
  12.3.2. Parenteral
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Hospital Pharmacies
  12.4.2. Retail Pharmacies
  12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  12.5.1. Japan
  12.5.2. China
  12.5.3. India
  12.5.4. ASEAN
  12.5.5. Australia & New Zealand
  12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.7. Europe Hepatitis Treatment Market Dynamics – Trends

13. LATIN AMERICA HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Hepatitis A
  13.1.2. Hepatitis B
  13.1.3. Hepatitis C
  13.1.4. Hepatitis D
  13.1.5. Hepatitis E
  13.1.6. Others
13.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Vaccines
  13.2.2. Anti-Viral Drugs
  13.2.3. Interferons
  13.2.4. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Oral
  13.3.2. Parenteral
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Hospital Pharmacies
  13.4.2. Retail Pharmacies
  13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.5.1. Brazil
  13.5.2. Mexico
  13.5.3. Argentina
  13.5.4. Venezuela
  13.5.5. Rest of Latin America
13.6. Latin America Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Hepatitis Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA HEPATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.1.1. Hepatitis A
  14.1.2. Hepatitis B
  14.1.3. Hepatitis C
  14.1.4. Hepatitis D
  14.1.5. Hepatitis E
  14.1.6. Others
14.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.2.1. Vaccines
  14.2.2. Anti-Viral Drugs
  14.2.3. Interferons
  14.2.4. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.3.1. Oral
  14.3.2. Parenteral
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.4.1. Hospital Pharmacies
  14.4.2. Retail Pharmacies
  14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.5.1. Gulf Cooperation Council (GCC) Countries
  14.5.2. Israel
  14.5.3. South Africa
  14.5.4. Rest of MEA
14.6. MEA Hepatitis Treatment Market - Opportunity Analysis Index, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Hepatitis Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Hoffmann- La Roche Ltd. (Switzerland)
  15.2.2. Gilead Sciences (U.S.)
  15.2.3. Novartis AG (Switzerland)
  15.2.4. Bristol-Myers Squibb (U.S)
  15.2.5. GlaxoSmithKline, plc.
  15.2.6. Merck and Co, Inc. (U.S)
  15.2.7. Johnson & Johnson Services, Inc. (U.S.)
  15.2.8. AbbVie Inc. (U.S.)
  15.2.9. Novira Therapeutics Inc. (U.S.)
  15.2.10. Eiger Biopharmaceuticals (U.S.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications